Sutro Biopharma (STRO) FCF Margin (2017 - 2025)
Sutro Biopharma recorded quarterly FCF Margin of 399.64% in Q4 2025, down 1.31% quarter-over-quarter from 394.47% in Q3 2025, and up 7562.0% year-over-year from 5.22% in Q4 2024.
Sutro Biopharma's FCF Margin history runs 9 years deep, the most recent figure standing at 399.64% for Q4 2025.
- In Q4 2025, FCF Margin rose 7562.0% year-over-year to 399.64%; the TTM figure through Dec 2025 stood at 206.73% (up 14832.0% YoY), while the FY2025 annual figure was 172.95%, up 13686.0% from the prior year.
- FCF Margin came in at 399.64% for Q4 2025 at Sutro Biopharma, down from 394.47% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 269.74% in Q3 2022 to a low of 1211.53% in Q1 2025.
- A 5-year average of 310.65% and a median of 322.16% in 2022 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin jumped 69027 bps in 2022 and plunged 71040 bps in 2025, its largest moves.
- Sutro Biopharma's FCF Margin stood at 86.01% in 2021, then sank by 303 bps to 346.93% in 2022, then soared by 104 bps to 14.71% in 2023, then slumped by 3330 bps to 475.26% in 2024, then rose by 16 bps to 399.64% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 399.64%, 394.47%, and 68.36% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Sutro Biopharma | 242.87 Mn | 242.87 Mn | - | -399.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -399.64% |
| Sep 30, 2025 | -394.47% |
| Jun 30, 2025 | -68.36% |
| Mar 31, 2025 | -1,211.53% |
| Dec 31, 2024 | -475.26% |
| Sep 30, 2024 | -779.61% |
| Jun 30, 2024 | 54.93% |
| Mar 31, 2024 | -501.13% |
| Dec 31, 2023 | 14.71% |
| Sep 30, 2023 | -214.10% |
| Jun 30, 2023 | -297.40% |
| Mar 31, 2023 | -484.16% |
| Dec 31, 2022 | -346.93% |
| Sep 30, 2022 | 269.74% |
| Jun 30, 2022 | -21.56% |
| Mar 31, 2022 | -612.79% |
| Dec 31, 2021 | -86.01% |
| Sep 30, 2021 | -420.52% |
| Jun 30, 2021 | -15.20% |
| Mar 31, 2021 | -223.78% |
| Dec 31, 2020 | -247.69% |
| Sep 30, 2020 | -122.91% |
| Jun 30, 2020 | -137.53% |
| Mar 31, 2020 | -272.61% |
| Dec 31, 2019 | -147.07% |
| Sep 30, 2019 | -130.21% |
| Jun 30, 2019 | -146.99% |
| Mar 31, 2019 | -236.66% |
| Dec 31, 2018 | -28.19% |
| Sep 30, 2018 | 602.53% |
| Jun 30, 2018 | -251.40% |
| Mar 31, 2018 | -259.19% |
| Dec 31, 2017 | -196.19% |